AllSci News
Asahi Kasei puts peptide TNF receptor 1 anatagonist into first-in-human study
Asahi Kasei Therapeutics Corp. has initiated a Phase I clinical trial for AK1940, a peptide-based selective antagonist of tumor necrosis factor receptor 1...
Asahi Kasei expands antiviral pipeline with completed acquisition of Aicuris Anti-infective Cures AG
Asahi Kasei Targets Antiviral Pipeline Expansion via Acquisition of Aicuris Anti-infective Cures AG
Lantern Pharma's LP-300 shows 8.3-month median progression-free survival in EGFR L858R lung cancer
Lantern Pharma (Nasdaq: LTRN) reported a median progression-free survival of 8.3 months for LP-300 in 16 patients with EGFR Exon 21 L858R-mutant non-small...
Eli Lilly building in vivo CAR-T capabilities via USD 7b acquisition of Kelonia Therapeutics
Eli Lilly and Company (NYSE: LLY) has agreed to acquire US-based Kelonia Therapeutics, Inc., a private Boston-headquartered gene therapy company, for up to...
AstraZeneca's tozorakimab meets primary endpoint in Phase III MIRANDA COPD trial
AstraZeneca (LSE/STO/NYSE: AZN) reported that tozorakimab met its primary endpoint in the Phase III MIRANDA trial, reducing the annualised rate of...
Novo Nordisk's etavopivat meets dual endpoints in Phase III sickle cell disease trial
Novo Nordisk reported that etavopivat met both co-primary endpoints in the Phase III HIBISCUS trial, reducing vaso-occlusive crisis events by 27% and...
Pasithea Therapeutics’ PAS-004 MEK inhibitor earns FDA Rare Pediatric Disease Designation for neurofibromatosis type 1
Pasithea Therapeutics (Nasdaq: KTTA), a clinical-stage biotech headquartered in Miami, announced that the US FDA has granted Rare Pediatric Disease Designation (RPDD)…
Astellas and Pfizer’s Padcev-Keyrtruda combo gains FDA Priority Review for muscle-invasive bladder cancer
Astellas Pharma Inc. (TSE: 4503), headquartered in Tokyo, and Pfizer Inc. (NYSE: PFE), headquartered in New York, announced that the US FDA…
Breakthrough Prize 2026 honors gene therapy pioneers, CRISPR innovators, and ALS gene discovery
The Breakthrough Prize Foundation announced the 2026 Breakthrough Prize winners on April 18, with the Life Sciences awards—presented alongside prizes in fundamental…
Jiangsu Hengrui’s Nectin-4 ADC gains China breakthrough status for cervical cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKEX: 600276), headquartered in Jiangsu province, China, announced that SHR-A2102, a Nectin-4–targeting antibody-drug conjugate (ADC) with a…
Landmark Bio secures USD 18.3m ARPA-H funding for extracellular vesicle manufacturing
Landmark Bio, a contract development and manufacturing organization (CDMO) based in Watertown, Massachusetts, has secured up to USD 18.3 million in...
Achieve Life Sciences secures USD 354m private placement for cytisinicline nicotine dependence program
Achieve Life Sciences (NASDAQ: ACHV), a specialty pharmaceutical company headquartered in Bothell, Washington, has announced a private placement of up to...
UCB acquires Neurona Therapeutics for USD 1.15b to expand epilepsy regenerative medicine platform
Belgium-based UCB (Euronext Brussels: UCB) has entered into a definitive agreement to acquire US-based Neurona Therapeutics, a privately held clinical-stage...
US Federal Circuit reinstates Teva’s patent on anti-CGRP headache drug in case against Eli Lilly
Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc. (Israel) received a reversal from the US Court of Appeals for the Federal…
MeiraGTx Holdings raises USD 100m in underwritten public offering
MeiraGTx Holdings plc (Nasdaq: MGTX) announced a USD 100 million underwritten public offering of ordinary shares, with proceeds directed toward extending...
The AllSci Brief
Free, systematic R&D and deal news. Daily.